The Relative Strength (RS) Rating for Roivant Sciences moved up into a new percentile Tuesday, as it got a lift from 61 to 71.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an RS Rating north of 80 as they begin their largest price moves. See if Roivant Sciences can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Roivant Sciences is working on a cup with handle with a 12.94 buy point. See if the stock can clear the breakout price in heavy trading.
Roivant Sciences showed 0% earnings growth in the latest quarterly report. Revenue gains came in at 23%.
The company earns the No. 135 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
